Gastric cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastric cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer https://clinicaltrials.eu/trial/study-of-ivonescimab-with-chemotherapy-combination-for-first-and-second-line-treatment-in-patients-with-advanced-or-metastatic-gastric-and-gastroesophageal-cancer/ Wed, 29 Apr 2026 15:06:47 +0000 https://clinicaltrials.eu/trial/study-of-ivonescimab-with-chemotherapy-combination-for-first-and-second-line-treatment-in-patients-with-advanced-or-metastatic-gastric-and-gastroesophageal-cancer/ This clinical trial focuses on patients with advanced or metastatic gastric cancer and esophagogastric junction cancer. The study evaluates a new treatment approach combining ivonescimab (also known as AK112/SMT112) with standard chemotherapy medications. The chemotherapy drugs used in this study include fluorouracil, irinotecan, paclitaxel, oxaliplatin, calcium levofolinate, and folinic acid.

The purpose of this research is to determine how well ivonescimab works when combined with chemotherapy in treating patients with advanced stomach and esophageal junction cancers. The study includes patients whose cancers may have specific biological markers (HER2, PD-L1, or Claudin18.2). These markers are proteins found on cancer cells that can affect how the cancer responds to treatment.

During the study, participants will receive ivonescimab through an intravenous infusion along with their chemotherapy treatment. The treatment will continue as long as patients show benefit from it and do not experience unacceptable side effects. Regular medical examinations and scans will be performed to monitor how the cancer responds to the treatment combination.

]]> Study on Gallium (68Ga) Tezatabep Matraxetan PET for Evaluating HER2 Status in Patients with Gastro-Esophageal and HER2-Low Breast Cancer https://clinicaltrials.eu/trial/study-on-gallium-68ga-tezatabep-matraxetan-pet-for-evaluating-her2-status-in-patients-with-gastro-esophageal-and-her2-low-breast-cancer/ Wed, 29 Apr 2026 14:25:09 +0000 https://clinicaltrials.eu/trial/study-on-gallium-68ga-tezatabep-matraxetan-pet-for-evaluating-her2-status-in-patients-with-gastro-esophageal-and-her2-low-breast-cancer/ This clinical trial is focused on studying two types of cancer: gastroesophageal cancer and breast cancer. The trial is particularly interested in cases where these cancers show a specific characteristic known as HER2-expression. HER2 is a protein that can affect the growth of cancer cells. The study will use a special imaging technique called PET/CT to look at how a new treatment, known by its code name 68Ga-ABY-025, interacts with these cancers. This treatment involves a solution that is injected into the body and helps to highlight cancer cells during the scan.

The purpose of the study is to evaluate how well the 68Ga-ABY-025 treatment can identify HER2 status in cancerous tumors and any spread of the disease, known as metastases. The study will involve patients with gastroesophageal cancer and those with a subtype of breast cancer called HER2-low. Participants will undergo PET/CT scans to see how the treatment is taken up by the cancer cells. This will help doctors understand more about the HER2 status of the tumors, which is important for planning the best treatment approach.

Throughout the study, participants will receive the 68Ga-ABY-025 treatment and have PET/CT scans to monitor the uptake of the treatment in their tumors. The study will also look at how the treatment affects the cancer over time, including any changes in the size or spread of the tumors. The trial aims to provide valuable information on the effectiveness of this new imaging method in assessing HER2 status, which could lead to better treatment strategies for patients with these types of cancer.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>